What is the dosing frequency of pimobendan (Vetmedin) for managing heart failure in dogs?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pimobendan Dosing for Dogs with Heart Failure

Pimobendan (Vetmedin) should be administered twice daily (every 12 hours) at a dose of 0.5 mg/kg/day divided into two equal portions for dogs with heart failure. 1

Dosing Details

  • Standard dose: 0.5 mg/kg/day divided into two approximately equal portions
  • Administration frequency: Every 12 hours (twice daily)
  • Formulation: Oral tablets (Vetmedin)

Evidence Supporting Twice Daily Dosing

The FDA-approved drug label for pimobendan clearly establishes the dosing frequency as twice daily. In the pivotal clinical trials that led to its approval, pimobendan was administered "0.5 mg/kg/day divided into 2 portions that were not necessarily equal, and the portions were administered approximately 12 hours apart" 1. This twice-daily dosing regimen demonstrated significant clinical efficacy in dogs with congestive heart failure due to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM).

Clinical Efficacy

Pimobendan's effectiveness with twice-daily dosing has been demonstrated in multiple clinical trials:

  • In the QUEST study, pimobendan administered at 0.4-0.6 mg/kg/day in divided doses significantly extended survival time compared to benazepril in dogs with congestive heart failure due to MMVD (median 267 days vs 140 days) 2

  • The EPIC study showed that pimobendan given at 0.4-0.6 mg/kg/day in divided doses to dogs with preclinical MMVD and cardiomegaly delayed the onset of congestive heart failure by approximately 15 months compared to placebo 3

Pharmacokinetic Considerations

The twice-daily dosing schedule aligns with pimobendan's pharmacokinetic profile. When administered orally, pimobendan reaches maximum plasma concentration (Cmax) at approximately 2.1 hours post-administration, with a half-life of about 1.8 hours 4. The active metabolite, O-desmethyl-pimobendan, has a longer half-life of approximately 5 hours 4. This pharmacokinetic profile supports the need for twice-daily administration to maintain therapeutic drug levels throughout the day.

Clinical Benefits of Twice-Daily Dosing

Twice-daily administration of pimobendan provides several important clinical benefits:

  • Sustained hemodynamic effects: Maintains positive inotropic effects throughout the 24-hour period
  • Reduced mitral regurgitation: Studies show pimobendan decreases mitral regurgitation severity 5
  • Improved cardiac function: Reduces heart size, which is associated with improved outcomes 6

Practical Administration Tips

  • Administer approximately 12 hours apart to maintain consistent drug levels
  • Can be given with or without food
  • If a dose is missed, administer as soon as possible, but do not double the next dose

Monitoring

When initiating pimobendan therapy, monitor:

  • Clinical signs of heart failure
  • Exercise tolerance
  • Respiratory rate and effort
  • Heart size via radiography or echocardiography at follow-up visits

Conclusion

The established dosing regimen for pimobendan in dogs with heart failure is twice daily (every 12 hours) at a total daily dose of 0.5 mg/kg divided into two approximately equal portions. This dosing schedule is supported by the FDA-approved label and multiple clinical trials demonstrating improved survival and quality of life in dogs with heart failure.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.